Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 399-401

  Yang, Guang ^a   Stapleton, Alan M F ^a   Wheeler, Thomas M ^a   Truong, Luan D ^a   Timme, Terry L ^a   Scardino, Peter T ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029966627     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
2. Bartek, J., Iggo, R., Gannon, J., and Lane. D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
3. Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A., and Millis, R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24: 469-476, 1993.
4. Visakorpt, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T., and Isola, J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883-887, 1992.
5. Navone, N. M., Troncoso, P., Pisters, L. L., Goodran, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657-1669, 1993.
6. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F , and Allred, D C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369-3373, 1993.
7. Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M , Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res., 1: 1111-1118, 1995.
8. Fox, S. B., Persad, R. A., Royds, J., Kore, R. N., Silcocks, P. B., and Colins, C C. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants? J. Urol., 150: 490-494, 1993.
9. Shurbaji, M. S., Kalbfleisch, J. H., and Thurmond, T. S. Immunohistochemical detections of p53 protein as a prognostic indicator in prostate cancer. Hum. Pathol., 26: 106-109, 1995.
10. Bauer, J. J., Sesterhenn, I. A., Mostofi, F K., McLeod, D. G., Srivastava, S., and Moul, J. W. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1: 1295-1300, 1995.
11. Thompson, T. C., Park, S. H., Timme, T. L., Ren, C., Eastham, J. A., Donehower, L. A., Bradley, A., Kadmon, D., and Yang, G. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene, 10: 869-879, 1995.
12. Van Veldhuizen, P. J., Sadasivan, R., Cherian, R., Dwyer, T., and Stevens, R. p53 expression in incidental prostatic cancer Am. J. Med. Sci., 305: 275-279, 1993
13. Miller, G. J., and Gygan, J. M. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J. Urol., 152: 1709-1713, 1994.